IsoRay, Inc., a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, has recently announced its latest medical breakthrough — a treatment for brain tumors developed from metastatic esophageal cancer using liquid Cesium-131 (Cesitrex®), which was proven successful in recent clinical trials.
Dr. Randy Sorum, a radiation oncologist, and Dr. Ryan Halpin, neurosurgeon at Capital Medical Center, Florida, managed to implant the GliaSite® Radiation Therapy System (RTS), a balloon catheter system that delivers high doses of radiation to the surgical bed, thereby minimizing radiation to uninvolved healthy brain tissue, into a 72 year-old male patient who was diagnosed with brain metastases resulting from an aggressive esophageal cancer. This patient had already unsuccessfully undergone surgery, external brain radiation, and stereotactic radio surgery in an attempt to clear and prevent metastasis.
Cesitrex ® is an exclusive product of IsoRay, and was recently FDA-cleared for internal radiation therapy of different types of cancer, such as brain, prostate, lung, colorectal, melanoma and gynecologic cancer. It allows for precise treatment, since it features a unique blend of high energy and a 9.7-day half-life, making it uniquely fast in giving off therapeutic radiation. It can be delivered through single seed applicators, implantable strands, and seed sutured mesh, but also through implantable devices, such as the GliaSite® radiation therapy system used in the treatment of brain cancer.
According to Dr. Sorum, “the unique benefit of GliaSite® is its capability to deliver radiation directly to the high risk areas for recurrence, unlike additional external beam radiation which likely would have damaging effects to healthy brain tissue. GliaSite® RTS in combination with Cesitrex® offers the additional benefit of improved quality of life for patients. Most important, the patient receiving Cesitrex® did great through the entire treatment process with no post-operative side effects to date.”
IsoRay CEO Dwight Babcock believes that both Cesium-131 brachytherapy seeds and GliaSite® RTS utilizing liquid Cesium-131 isotope will be able to take on difficult cancers and improve patients’ life quality. This company wishes to implement Cesitrex® as a standard care for treatment of multiple cancers and GliaSite ® RTS as a standard care in the treatment of brain cancer.